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Abstract  17 
Pharmaceutical cocrystals have attracted increasing attention over the past decade 18 
as an alternative way to modify the physicochemical properties and hence improve 19 
the bioavailability of a drug, without sacrificing thermodynamic stability. Our 20 
previous work has demonstrated the viability of in-situ formation of 21 
ibuprofen/isonicotinamide cocrystal suspensions within a matrix carrier via a 22 
single-step hot-melt extrusion (HME) process. The key aim of the current work is to 23 
establish optimised processing conditions to improve cocrystal yield within 24 
extruded matrices. 25 
The solubility of each individual cocrystal component in the matrix carrier was 26 
estimated using two different methods, calculation of Hansen solubility parameters, 27 
and Flory-Huggins solution theory using melting point depression measurement, 28 
respectively. The latter was found to be more relevant to extrusion cocrystallisation 29 
because of the ability to predict miscibility across a range of temperatures. The 30 
predictions obtained from the F-H phase diagrams were verified using ternary 31 
extrusion processing. Temperatures that promote solubilisation of the parent 32 
reagents during processing, and precipitation of the newly formed cocrystal were 33 
found to be the most suitable in generating high cocrystal yields. The incorporation 34 
of intensive mixing/kneading elements to the screw configuration was also shown 35 
to significantly improve the cocrystal yield when utilising a matrix platform. This 36 
work has shown that intensive mixing in combination with appropriate temperature 37 
selection, can significantly improve the cocrystal yield within a stable and low 38 
viscosity carrier during HME processing. Most importantly, this work reports, for 39 
the very first time in the literature, the use of the F-H phase diagrams to predict the 40 
most appropriate HME processing window to drive higher cocrystal yield.  41 
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INTRODUCTION 42 
Our previous work successfully demonstrated the feasibility of manufacturing 43 
(ibuprofen/isonicotinamide) Ibu-IsoNA cocrystals in the presence of a 44 
pharmaceutical excipient1 using mechanochemical HME processing. From our 45 
previous work, it was shown that xylitol was the most appropriate (from the 4 46 
selected). Xylitol is a chemically stable pharmaceutical excipient and food additive 47 
with a low melting viscosity at specified extrusion temperature2. In addition, xylitol 48 
was observed to exhibit rapid solidification upon cooling, which was also 49 
considered pertinent for the successful extrusion of a cocrystal suspended in the 50 
excipient matrix. The extruded cocrystal/xylitol suspensions exhibited further 51 
enhanced ibuprofen dissolution rate when compared with the analogous cocrystal 52 
extruded devoid of any excipient. However, the final cocrystal yield within the 53 
matrix was still unsatisfactory. In our previous study, a small amount of both 54 
reagents were rendered amorphous within the matrix during extrusion processing. 55 
Subsequently, increased cocrystal yield was observed during storage, particularly 56 
when the formulation was placed in a humid environment3.  57 
It has been indicated in the literature that cocrystallisation by melting or 58 
mechanochemical processes may not be as efficient as solution methods, due to 59 
limited activity of the reactant molecules4. But with the presence of a non-60 
complementary carrier, both cocrystal reagents could ‘dissolve’ in the liquefied 61 
carrier, resulting in a similar cocrystallisation mechanism to traditional solvent 62 
approach, albeit in an increased viscosity environment (due to the viscous nature of 63 
the molten excipient). However, since the ‘solvent’ (matrix carrier) in a HME system 64 
will not be removed post processing, the solubility of the cocrystal within the carrier 65 
pool should be limited such that precipitation of the product is encouraged. It is 66 
therefore obvious that the phase behaviour between individual cocrystal 67 
components (including both the reagents and the product of cocrystallisation) and 68 
the matrix carrier may significantly influence the extent of cocrystal conversion. A 69 
carrier melt pool ‘solvent’ in which the reagents and the cocrystal show such 70 
distinctive solubility differences, or a temperature that drives a solubility difference 71 
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between reagents and cocrystal within a given carrier could be used to enhance the 72 
cocrystal yield. Therefore, this work is aimed at assessing the solubility of the 73 
cocrystal components in a given matrix as well as investigating how HME processing 74 
temperature settings may influence solubility and correlation to cocrystal yield. Two 75 
different methods have been used to achieve such aims, namely solubility parameter 76 
comparison and the adaptation of Flory-Huggins theory using the melting point 77 
depression method.  78 
It has also been reported in the literature that increased mixing and shear 79 
intensity could facilitate cocrystal yield5. Therefore, not only can we expect 80 
temperature and miscibility to change yield but process parameters such as screw 81 
design that is known to alter extrudate properties6, and operating efficiency7 must 82 
be considered. Hence, another important aspect to this research paper is to identify 83 
the impact of screw geometry and to rationalize screw configuration for improved 84 
cocrystal yield during ternary extrusion processing. Screw configuration designs 85 
conveying increased shear intensity were investigated for their influence on 86 
cocrystal yield.  87 
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MATERIALS AND METHODOLOGY 88 
Materials 89 
Ibuprofen, isonicotinamide, and xylitol were purchased from Sigma-Aldrich (St. 90 
Louis, MO, USA). All other chemical reagents used were of analytical grade.  91 
 92 
Calculating solubility parameters 93 
The use of solubility parameters to predict the miscibility and/or compatibility of 94 
pharmaceutical materials has been extensively reported. Such information is often 95 
used to set criteria for excipient selection in formulation design8–10, or for coformer 96 
selection in cocrystal screening11,12. Estimation of miscibility between any two 97 
components (Ibu vs. IsoNA, Ibu vs. xylitol, IsoNA vs. xylitol and, the 1:1 Ibu-IsoNA 98 
cocrystal vs. xylitol) within the cocrystal suspension system was performed by 99 
comparing the total solubility parameter (δt) for each individual component. δt was 100 
calculated using the Hansen partial solubility parameters (δd, δp & δh) based on the 101 
group contribution method of Fedors13 and Van Krevelen-Hoftyzer14,15:  102 
    Equation 1 103 
 104 
 105 
Equation 2 106 
 107 
Where Fdi is the group dispersion component contributing to the disperse forces δd, 108 
Fpi the plane symmetry factor giving polar group forces δp, Ei the group contribution 109 
to hydrogen bonding energy and V the molar volume from Hildebrand analysis.  110 
 111 
Sample preparation for melting point depression measurements 112 
All substances were desiccated over silica gel to guarantee minimum moisture 113 
content prior to use. The reference cocrystal was grown via slow evaporation from a 114 
methanol solution. The conversion from Ibu and IsoNA to their equimolar cocrystal 115 
was confirmed by thermal analysis, powder x-ray diffraction and spectroscopy as 116 
described in our previous work1. Binary physical mixtures containing compound A 117 
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(the reference cocrystal or individual parent reagent, respectively), and compound 118 
B (the matrix carrier xylitol) were prepared, using a mortar and pestle, at 119 
predetermined compositions (100%, 95%, 90%, 85%, 80%, 75% and 70% w/w of 120 
compound A) in triplicate. The resulting mixed powders were desiccated until 121 
further use. 122 
 123 
Differential Scanning Calorimetry (DSC) 124 
Melting point depression experiments for the binary physical mixtures were 125 
performed on a model DSC 8000 power compensation differential scanning 126 
calorimeter (Perkin-Elmer, Windsor, Berkshire, UK). The machine was calibrated, at 127 
the respective heating rates, for melting point and heat of fusion using indium and 128 
zinc, respectively, prior to the experiments. Both the reference and sample 129 
chambers were purged with dry nitrogen at a flow rate of 40mL/min to maintain an 130 
inert atmosphere. 3-5mg of sample was accurately weighed to aluminium pans and 131 
crimped using an aluminium pan lid. The crimped pan set was then subjected to a 132 
thermal ramp at 1°C/min from 80°C to 135°C. For samples containing IsoNA, a 133 
200°C/min heating rate and 40mL/min purged helium were used to avoid 134 
compositional variations associated with IsoNA degradation at low heating rates 135 
(heating rate dependent weight loss observed in TGA analysis, data submitted in the 136 
supplementary material). Samples containing IsoNA were subjected to a 30-minute 137 
isothermal treatment at 100°C prior to the DSC ramping over a range from -60°C to 138 
230°C. Such a pre-treatment was employed to provide an extended period so that 139 
any inadequate solubilisation caused by the fast heating16 might be compensated. 140 
100°C was chosen as the isothermal temperature as it was above the melting of 141 
xylitol, yet below the onset of significant IsoNA weight loss (120°C if heated at 142 
1°C/min, data shown in supplementary material). The determination of the 143 
isothermal time, on the other hand, was based on whether stabilised depression of 144 
∆H(IsoNA) was attainable during preliminary screening (data included in 145 
supplementary document). All values of melting points used in this study were the 146 
end temperature of the melting event.  147 
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 148 
Powder X-ray Diffraction (PXRD) 149 
PXRD was performed using a MiniFlex II desktop powder X-ray diffractometer 150 
(Rigaku Corporation, Kent, England). The machine is equipped with Cu Kα radiation, 151 
at a voltage of 30 kV and a current of 15 mA. The scanning was conducted across a 152 
2Θ scanning range from 1.5-40° at 2.0°/min and a sample width of 0.03°. The peak 153 
area underneath the cocrystal characteristic peak at 3.3° 2Θ for each sample was 154 
used to determine the cocrystal yield17. A series of physical mixtures containing the 155 
reference cocrystal and xylitol at 10 different cocrystal loadings, 10, 20, 30, 40, 50, 156 
60, 70, 80, 90 & 100% w/w, respectively, were prepared through gentle grinding. 157 
The blended samples were placed into a top-fill glass sample holder (0.2mm well 158 
depth) for analysis. The peak area was calculated using Integral Int. Calculation 159 
software (Integral analysis for windows, Version 6.0, Rigaku Corporation) with 160 
manual background subtraction and an integration region set between 161 
[2.400~4.050° 2θ]. A calibration curve, (R2=0.998) was constructed using linear 162 
regression between the average peak area and cocrystal concentration in the blends. 163 
The calibration curve was validated for linearity, accuracy, precision, LoD and LoQ 164 
according to the methods recommended in the ICH guidelines18. The results from 165 
the construction and validation of the quantitative PXRD analysis were published as 166 
supplementary data for our previous work1. 167 
 168 
Determination of cocrystal yield 169 
With the standard calibration curve established and validated, the cocrystal yield in 170 
the melt-extruded suspensions can be calculated as follows: 171 
 172 
Cocrystal	yield	(%) =
Measured	cocrystal	concentration	(%)
Theoretical	fully	converted	content	(%)
× 100% 
 173 
Where the theoretical fully converted content in this work was 50% as xylitol 174 
loading was kept constant at 50wt% for all cases. 175 
 176 
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Hot-melt extrusion (HME) 177 
Hot-melt extrusion was conducted using a co-rotating 20:1 twin screw Rondol 178 
Microlab 10mm compounder (Rondol Technology Ltd., Staffordshire, UK) equipped 179 
with a force feeder and an open end. Raw materials were accurately weighed, 180 
pestle-mixed in a ceramic mortar, and subsequently fed at a fixed rate of 20rpm 181 
using the auxiliary single-screw force feeder. A screw speed of 10rpm was used for 182 
the main extruder in all extrusion experiments. Table 1 illustrates the temperature 183 
profile (TP) settings used in this work. In particular, the temperature for the feeding 184 
zone (Zone 0) for all formulations was kept constant at 60°C to allow adequate solid 185 
conveying from the feed hopper. The following Zone 1 was designed as the melting 186 
zone with temperature set at 80°C, 92°C, 100°C, 110°C and 115°C, respectively. To 187 
ensure the production of a solid extrudate rather than a melt pool at the barrel exit, 188 
Zone 2 & Zone 3 were designed as cooling zones and set with gradually decreasing 189 
temperatures (Table 1).  190 
As detailed in Table 2, three different screw configuration profiles (SCP) were 191 
applied to modify the mixing and shear intensities and to understand the link to 192 
cocrystal yield during HME. SCP1 was assembled using conveying elements only. 193 
SCP2 incorporated two kneading regions each configured as a 90° neutral-staggered 194 
kneading block sandwiched by two 60° forward-staggered kneading blocks. In SCP3, 195 
additional kneading blocks were included in each kneading region to provide 196 
further enhanced shearing within the melt stream.  197 
Extrusion was repeated in triplcate for each formulation and the average 198 
residence time and system torque were recorded in Table 3. The resulting 199 
extrudates were collected directly from the open barrel end and subsequently 200 
pulverized using a mortar and pestle once cooled. The powdered samples were 201 
sieved through a 212μm mesh sieve (Scientific Laboratory Supplies Ltd, 202 
Nottingham) and then desiccated in non-humid environment prior to further 203 
analysis. Note that all formulations extruded in this work contained a fixed xylitol 204 
content of 50% w/w. 205 
 206 
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Statistical analysis  207 
Statistical analyses were conducted using GraphPad Prism one-way analysis of 208 
variance with Tukey’s multiple comparison tests. The confidence interval was set 209 
automatically as 95%. The computed statistics provide a significance value (P) for 210 
each individual comparison. A “P” value less than than 0.05 indicates significant 211 
difference.   212 
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FLORY-HUGGINS THEORY AND DATA TREATMENT 213 
Flory-Huggins theory is a comprehensively used mathematical theory, developed 214 
independently by Flory19,20 and Huggins21,22, for modelling the thermodynamics of 215 
binary polymer-solvent mixtures. In this model, the size disparity between the two 216 
components is taken into account when determining the entropy of mixing of a 217 
binary system consisting of unequal-sized molecules. The theory assumes 218 
hypothetical lattice sites that accommodates either an individual solvent molecule 219 
or a polymer chain segment. It is assumed that the macromolecular polymer is 220 
equivalently divided into a number of chain segments that each occupies the same 221 
volume on a lattice as a solvent molecule in order to utilise the usual expression of 222 
entropy of mixing. The free energy of mixing ΔGmix for such a binary system, 223 
according to F-H theory, can be expressed using Eq. 323: 224 
 225 
 226 
Equation 3 227 
Where Φ is the volume fraction of solvent (the small molecular component), R is the 228 
molar gas constant, T is the temperature in the Kelvin, m is the number of polymer 229 
chain segments (typically calculated as the ratio of the volume of a polymer chain to 230 
that of a solvent molecule), and  χ is the F-H interaction parameter between polymer 231 
and solvent molecules19. In such an expression, the obtained ΔGmix shows clear 232 
composition dependency. Mathematically, the entropy factor (the first two terms on 233 
the right-hand side of Eq. 3) of the expression favours mixing by resulting in non-234 
positive numerical values at all times. The enthalpy factor (the third term), in 235 
contrast, shows influence on the mixing preference through the value of χ. For 236 
systems exhibiting adhesive bonds favouring miscibility (negative χ values) and/or 237 
no specific bonding between species whatsoever (χ = 0), the ΔGmix can remain 238 
negative throughout the entire composition range. Whereas for systems that exhibit 239 
unfavourable mixing (positive χ values), the ΔGmix only remains negative until a 240 
certain threshold value of χ and becomes positive at points beyond.  241 
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By adapting the concept of the F-H theory, melting point depression theory 24,25 242 
may be used in the calculation of χ value for drug-polymer binaries where the 243 
following equations, Eq. 4 and Eq. 5, are applied16,26–31: 244 
 245 
 246 
Equation 4 247 
 248 
Equation 5 249 
Where Tm is the melting temperature of drug in the binary mixture; Tm0 and ∆H are 250 
the melting temperature and the enthalpy of fusion, respectively, for the pure drug 251 
substance.  252 
Based on the expression in Eq. 5, the estimation of the dimensionless, enthalpic 253 
energy parameter χ is related to both temperature and composition. Using 254 
experimentally obtained Tm values for binary mixtures of different drug-polymer 255 
compositions, the corresponding value of χ can be calculated. In practice, however, 256 
the measurement of Tm is always rendered unfeasible at low drug loadings. Ability 257 
to extrapolate the value of χ beyond experimentally feasible temperatures is then 258 
crucial to the establishment of phase behaviour throughout the entire composition 259 
range. In the current literature, a first order relationship between χ and the 260 
reciprocal temperature (Eq. 6) has been commonly used for such purposes23,29: 261 
 262 
Equation 6 263 
Constants A and B can be fitted using the experimental data, allowing the free 264 
energy of mixing expression to be become:  265 
 266 
 267 
Equation 7 268 
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Additionally, by setting the second derivative of the ΔGmix to Zero, one can 269 
achieve Eq. 8 to determine the position of the spinodal curve32, which depicts the 270 
boundary of phase separation in the solid state:  271 
 272 
 273 
Equation 8 274 
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RESULTS AND DISCUSSION 275 
Cocrystallisation using a conventional solution approach is generally conducted in 276 
ternary systems consisting of a conformer, drug and a solvent or a mixture of 277 
solvents. Solubility information between individual cocrystal components and the 278 
solvent is fundamental in establishing phase diagrams that are generally used to 279 
describe the conditions needed for cocrystal formation33–37. Moreover, it has been 280 
shown that coformer solubility in solvent during liquid-asssited mechanochemical 281 
synthesis plays an important role, influencing cocrystallisation efficiency4,38–43. 282 
In our work, we consider the synthesis of a cocrystal in a molten carrier to be 283 
similar to that in the presence of a traditional organic solvent. The liquefied carrier 284 
serves as a viscous solvent to accommodate the parent reagents, hence providing 285 
increased degrees of freedom for hetero-molecular collision and thus improved 286 
cocrystallisation efficiency. In previous research, it has been suggested that the 287 
solvent should not be capable of forming secondary interactions with any cocrystal 288 
reagents such that the interactions between the reagents are still favoured. In 289 
respect of HME, processing conditions may be controlled in order to enhance 290 
interaction between cocrystal reagents and limit reaction with meltable carrier 291 
‘solvent’44,45. In addition, we should also remember that unlike a traditional organic 292 
solvent used for either solvent-based cocrystallisation or liquid-assisted grinding, 293 
the molten carrier used during HME will not evaporate after processing, but rather 294 
remains as a matrix. As such the pharmaceutical excipient used as a matrix carrier 295 
should be suitable to meet the end use of the drug product. In particular, the 296 
dispersed cocrystal phase must have limited solubility in the matrix carrier at 297 
decreased temperature when the formulation exits the extruder in the solid-state. 298 
Without this condition being met there may be a high probability that an amorphous 299 
dispersion of individual coformer molecules, rather than a cocrystal suspension 300 
would form within the carrier46. 301 
To aid understanding of this hypothesis, an illustration showing the preparation 302 
of cocrystal suspensions in a single-step HME is provided in Figure 1. Using this 303 
method, the manufacture of cocrystal suspensions may be regarded as a sequence of 304 
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events in the direction of melt flow. Ideally, the ternary physical mixture is fed into 305 
the extruder feed zone as mixed solids. The mixed solids are then conveyed to a 306 
melting zone where a melt pool forms. The presence of such a melt pool provides a 307 
medium for cocrystallisation and additionally may also significantly improve 308 
reaction kinetics due to the increased mobility within the molten matrix47. The 309 
processing temperature in the following zone should be decreased sufficiently to 310 
assist precipitation of the newly formed cocrystals from the carrier melt, whilst the 311 
final zone ought to be designed with a further decreased temperature to ensure 312 
solidification of the carrier, and thus, formation of an intimately mixed cocrystal 313 
suspension. Consequently, it is extremely important to understand solubility 314 
behaviour and miscibility of individual cocrystal components and the carrier. 315 
Interestingly, in the scenario presented, solubility and component miscibility must 316 
be considered both in the melt and also in the solid-state. In this work, we present 317 
two extensively reported methods for the purposes of advancing our understanding 318 
of this complex cocrystal manufacturing process. 319 
 320 
Solubility Parameters 321 
The Hansen solubility parameters (HSP) calculated using the group contribution 322 
method has enabled the prediction of solid-solid solubility of pharmaceutical 323 
relevant materials8,9. For drug-excipient combinations, the Forster predictions 324 
consider a Δδt < 7.0 MPa1/2 indicative of significant miscibility and formation of glass 325 
solutions during melt-extrusion, whereas a Δδt > 10.0 MPa1/2 denotes a lack of 326 
miscibility and limited ability to form glass solutions10. Later, Velaga et al., explored 327 
the correlation between solubility parameter calculations, predicted drug-coformer 328 
miscibility and the feasibility of cocrystallisation11. In this important work, it was 329 
shown that those systems capable of successfully forming cocrystals were 330 
manufactured from systems that were miscible. The authors therefore concluded 331 
that drug-coformer miscibility was necessary in order to attain cocrystallisation, 332 
and that the use of solubility parameters was an efficient method for screening 333 
coformer candidates. 334 
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In the light of the above, our current study considered that Ibu and IsoNA should 335 
show significant good miscibility thus encouraging cocrystallisation. Moreover, our 336 
selected carrier (Xylitol) should exhibit limited miscibility with the formed cocrystal. 337 
Within this investigation our hypothesis is that dissolution of the parent reagents 338 
within molten xylitol could increase activity of the reactants hence increasing 339 
interspecies collision, leading to improved cocrystal yield. However, interaction 340 
between xylitol and each individual cocrystal reagent must not surpass that 341 
between the parent reagents.   342 
The solubility parameter values for parent reagents, cocrysal and xylitol were 343 
calculated and compared. Table 4 gives a list of the identified component group 344 
contributions and the calculated total solubility parameter for each compound. The 345 
subsequent calculation of the total solubility parameter difference Δδt, is as follows: 346 
Δδt (Ibu/IsoNA) is 1.95 MPa1/2, Δδt (Ibu/xylitol) and Δδt (IsoNA/xylitol) are 13.56 347 
MPa1/2 and 11.61 MPa1/2, respectively, whilst Δδt (cocrystal & xylitol) is 13.74 348 
MPa1/2. According to Forster et al., the Δδt values obtained confirm, theoretically, 349 
that Ibu and IsoNA are strongly miscible, whilst xylitol is less miscible with both the 350 
cocrystal reagents and the respective equimolar cocrystal. The predicted 351 
immiscibility between xylitol and the Ibu-IsoNA cocrystal may be beneficial in 352 
precipitation of cocrystal product from the excipient following extrusion. Unlike 353 
cocrystallisation using conventional solvents in which cocrystal production is 354 
facilitated through evaporation of solvent, formulating a cocrystal suspension via 355 
HME is fundamentally different in the sense that the excipient carrier solidifies 356 
rather than evaporates after processing. Therefore precipitation, in such cases, can 357 
only occur when the newly formed cocrystal exhibits a significantly reduced 358 
miscibility/solubility with the carrier excipient. Interestingly, the limited miscibility 359 
predicted using the solubility parameter approach between xylitol and each 360 
individual parent reagent (Ibu and IsoNA), presents a complex scenario for 361 
evaluation of such a system. In such cases the limited miscibility may render the 362 
presence of xylitol a physical hindrance thus preventing reaction of the parent 363 
reagents and formation of cocrystal. However, it must be noted that the calculated 364 
solubility parameter values do not take in to account the shearing forces and 365 
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temperatures involved during extrusion, which may promote reaction of the two 366 
components. Moreover, miscibility predictions are very much dependent upon 367 
temperature and the relationship to the solubility parameter. Comprehensive group 368 
contribution information throughout a greater temperature scale other than 369 
25°C48,49 is still lacking, rendering the HSP method somewhat less useful while 370 
assessing the mixing behaviour at significantly elevated temperatures during the 371 
HME processing. Furthermore, in our previous work describing the manufacture of 372 
cocrystals via HME we indeed demonstrated the successful formation of an 373 
equimolar Ibu-IsoNA cocrystal from a ternary mixture with xylitol1.  374 
 375 
Melting Point Depression Measurement and Construction of Phase Diagrams 376 
The use of Flory-Huggins theory in combination with melting point depression 377 
measurements, has recently been utilised to better understand the relationship 378 
between binary mixing behaviour and temperature. In particular, F-H theory has 379 
been shown to be useful in determining the impact of processing temperature on 380 
the miscibility of components during melt extrusion16,29,31,50. Although F-H theory 381 
has been used for polymeric and other viscous systems, the high melt or rubber 382 
viscosity provide a kinetic barrier to dissolution. The hindered mobility in these 383 
systems often leads to an underestimation of solubility. In this current study 384 
involving xylitol, a small molecular weight sugar alcohol, the similarity of molecular 385 
weight between components and the low viscosity of xylitol reduce the likelihood of 386 
underestimation. In the original F-H theory, a hypothetical ‘lattice’ in space is 387 
assumed as the spatial volume that a polymer chain segment or a solvent molecule 388 
occupies. The fact that both the solute and solvent in this case are small molecules 389 
reduces the extent of dissimilarity in molecular size. In our consideration, instead of 390 
assuming a hypothetical space, we took into account the size dissimilarity directly 391 
by calculating the volume ratio of a carrier molecule to a drug molecule using their 392 
true densities and respective molecular weights (Table 5). 393 
Ibuprofen, has a lower melting temperature (76.86±0.08°C) relative to xylitol 394 
(95.32±0.14°C) and thus it is reasonable to assess xylitol solubility in molten 395 
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ibuprofen. It is also worth noting that when determining the mixing between xylitol 396 
and ibuprofen, xylitol is considered the ‘solute’ while ibuprofen is considered the 397 
‘solvent’. In the design of the latter melt extrusion experiments, ibuprofen and 398 
xylitol were subjected to fusion simultaneously. The true density, Tm and ΔH for IBU, 399 
IsoNA, xylitol and the reference cocrystal are listed in Table 5. The melting 400 
endotherms are shown in Figure 2 for ibuprofen-xylitol, isonicotinamide-xylitol and 401 
cocrystal-xylitol binary systems, respectively. It is worth noting that a DSC heating 402 
rate of 1°C/min was applied to both the xylitol/Ibu and cocrystal/xylitol systems, 403 
whilst 200°C/min was employed for the IsoNA/xylitol system. This was because 404 
IsoNA was discovered to sublime hence undergoing tremendous weight loss before 405 
reaching its melting point. Such sublimation was heating rate-dependent, with 406 
prominently increased loss of weight if sample was treated with extremely slow 407 
heating such as 1°C/min, but negligible weight loss if heated using 200°C/min (See 408 
Appendix 1 in the supplementary document). Our previous publication has 409 
investigated the influence of DSC heating rate upon the construction of drug-410 
polymer miscibility phase diagram when applying the FH theory to the melting 411 
point depression data16. It was shown in that work the use of high DSC heating rates 412 
could result in underestimation of the metastable region and inaccurate prediction 413 
of a poor miscibility limit. The authors attributed such inaccuracy to inadequate 414 
dissolution of molecules from within the drug crystalline lattice into the polymer, 415 
when increased DSC heating rates were applied. However, in the current work, the 416 
dissolution of IsoNA in molten xylitol does not necessarily suffer from the same 417 
extent of time-dependence, since xylitol is a small molecular component with 418 
significantly lower melting viscosity. Though that being said, a compensational 419 
isotherm was conferred on the IsoNA/xylitol mixtures, prior to the DSC experiments. 420 
This isotherm was performed at 100°C, well below the onset of IsoNA weight loss 421 
(Appendix 1 in the supplementary document), but above the melting of xylitol, 422 
sufficient to create a melt pool of xylitol for IsoNA to dissolve in. A time frame of 30 423 
min was selected from a series of tested periods (15, 30 and 45 min) since it 424 
provided a stabilised heat of fusion depression (see Appendix 2 in the 425 
supplementary document).  426 
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Melting depression was evident in each system, for example in the xylitol/Ibu 427 
blends, the end point for the xylitol melting was measured to shift gradually from 428 
95.32±0.14°C to 94.84±0.07°C with gradual increase of the ibuprofen content from 429 
0-30wt% (Figure 2a, for mean and standard deviation of individual measurement 430 
please see Appendix 3 in the supplementary document). Interestingly, although 431 
ibuprofen melted at a lower temperature than xylitol, the presence of the latter was 432 
observed to depress the melting of ibuprofen from 78.86±0.08°C to (76.44±0.10°C). 433 
Similarly, increase of the xylitol content in both IsoNA/xylitol and cocrystal/xylitol 434 
systems also resulted depression of IsoNA and the cocrystal melting from 435 
169.79±1.62°C to 150.52±0.42°C (Figure 2b), and from 120.96±0.06°C to 436 
115.43±0.07°C (Figure 2c), respectively (see Appendices 4 and 5 in the 437 
supplementary document for mean and standard deviation of individual 438 
measurement). A small endothermic event (141.29±0.21 °C) was also observed on 439 
the pure IsoNA DSC thermogram, shortly prior to the main melting at 169.79±1.62°C 440 
(Figure 2b). This corresponds to the thermal behaviour of IsoNA polymorph 2 (CSD 441 
refcodes EHOWIH, EHOWIH01)51. The small initial endotherm has been previously 442 
reported to be the result of solid-solid phase transition into modified forms which 443 
would then melt as IsoNA polymorph 252.  444 
Using the melting depression data, the Flory-Huggins interaction parameter, χ, 445 
was calculated for each respect system (across experimentally measurable 446 
temperatures) using Eq. 5 and plotted against the corresponding reciprocal of Tm in 447 
Figure 3. Linear regression shows reasonably good fits (R>0.94) for all three 448 
systems. As discussed before, although our previous paper has shown the impact of 449 
heating rate on the construction of the F-H phase diagrams, and more directly on the 450 
values of χ16, such impact was again considered not significant in the current work, 451 
due to the limited kinetic hindrance (since all species involved were small 452 
molecules) present in the system. Indeed, in Figure 3b, negative χ values were 453 
calculated for the IsoNA/xylitol blends with increased negativity when increasing 454 
the xylitol content. A negative A value calculated from the linear fit (Eq. 6), in 455 
particular, suggests negative Gibb’s free energy and favourable mixing between the 456 
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two species due to favourable entropic contributions in the system. Interestingly for 457 
the xylitol/ibuprofen and the cocrystal/xylitol blends, both χ-1/T plots resulted in 458 
positive A values instead (Figure 3a and 3c, respectively), suggesting unfavourable 459 
mixing and positive Gibb’s free energy at the depressed melting temperatures of 460 
xylitol and the cocrystal.  461 
A plot of ΔGmix/RT versus compound fraction for each system is shown in Figure 462 
4 based on Eq. 7, denoting the variation of free energy of mixing as a function of 463 
both composition and temperature. It is worth nothing that the temperatures 464 
chosen for the calculation of ΔGmix/RT were the nearest integers to the following 465 
criteria: (1) above ibuprofen melting endpoint – 80°C; (2) onset of xylitol melting – 466 
92°C; (3) end of xylitol melting – 95°C; (4) onset of the equimolar Ibu-IsoNA 467 
cocrystal – 120°C; and (5) intermediate temperatures between (3) and (4) – 100°C, 468 
110°C and 115°C, respectively. Generally speaking, a negative energy value is 469 
indicative of mixing in which attraction forces between species are stronger than 470 
that between like molecules promoting the occurrence of a homogeneous phase, 471 
whereas a positive energy value signifies immiscibility. The shape of the energy 472 
curve at a specific temperature is also informative. A concave curve is often 473 
observed in homogeneous phases revealing negative energy values throughout the 474 
entire composition range. A convex shape, on the other hand, suggests spontaneous 475 
phase separation for all compositions at this temperature. A sigmoidal curve, 476 
therefore, is indicative of concentration dependent phase behaviour at the defined 477 
temperature.  478 
In Figure 4a, it is shown that the energy of mixing between ibuprofen and xylitol 479 
is almost zero throughout the entire composition range when the temperature is 480 
95°C. Concave energy curves are observed for both 92°C and 80°C, while convex 481 
curves are observed from 100°C to 120°C. Such energy diagrams suggest that 482 
ibuprofen is less miscible with xylitol when temperature elevates, agreeing with the 483 
previously obtained positive A and χ values. A similar trend is also observed for the 484 
cocrystal/xylitol blends in Figure 4c where the energy curve changes from a 485 
concave profile at 80°C (favourable mixing) to approximating a plateau (majority of 486 
the energy values just above zero) when the temperature reaches 115°C. Further 487 
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increase of the temperature to 120°C resulted in a convex energy curve, suggesting 488 
limited miscibility at such a temperature. The IsoNA/xylitol blends, on the other 489 
hand, exhibited concave energy curves from 110-120°C (Figure 4b), indicative of 490 
complete miscibility between IsoNA and xylitol across the entire composition range 491 
at these temperatures. Interestingly, although the energy curve was sigmoidal at 492 
100°C, all the values of ΔGmix/RT were negative, suggesting favoured interspecies 493 
mixing at this temperature too.  494 
Derived from these energy curves, the thermodynamic (temperature-495 
composition) binary phase diagrams were constructed for xylitol/ibuprofen, 496 
IsoNA/xylitol and the reference cocrystal/xylitol mixtures, respectively, enabling 497 
the prediction of binary miscibility as a function of temperature. From Figures 5a 498 
and 5c, it can be seen that a Lower Critical Solution Temperature (LCST) behaviour 499 
was evident for both the xylitol/ibuprofen and the cocrystal/xylitol systems, with 500 
the calculated critical temperatures to be approximately 95°C and 114°C, 501 
respectively. The LCST is the shared minimum of the two F-H theoretical curves, the 502 
concave spinodal and binodal lines, respectively.  A LCST behaviour denotes 503 
complete miscibility in all proportions at temperatures below the LCST. In the 504 
previous energy curves, a plateau line was reached at 95°C to distinguish the 505 
boundary between complete miscibility (concave energy curve) and limited 506 
miscibility between xylitol and ibuprofen. A similar plateau was also observed at 507 
115°C to denote complete and limited miscibility boundary between the cocrystal 508 
and xylitol. Therefore, the LCST behaviour observed for the two systems agrees with 509 
the previous energy curve indications and is suggesting complete miscibility 510 
between xylitol and ibuprofen below 95°C and that between the cocrystal and xylitol 511 
below 114°C (or 115°C if not taking into account the 1°C discrepancy between the 512 
LCST and the ΔGmix/RT plateau), respectively. Such result is most interesting yet 513 
counter-intuitive as it is advising complete miscibility between these species at 514 
room temperature. Although the existence of an LCST for small molecules is rare, 515 
there are previous reports of immiscibility between ibuprofen and xylitol when both 516 
compounds are molten9. Complete miscibility between the Ibu-IsoNA cocrystal and 517 
xylitol, on the other hand, could contradict with the “immiscible with newly formed 518 
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cocrystal” criteria for carrier screening in the first place. However, one must 519 
remember that all species are in the solid crystalline state at room temperature, 520 
hence the likelihood of cocrystal dissolution in the rigid xylitol crystalline lattices 521 
would be extremely small due to strong kinetic hindrance.  522 
From Figure 5b, an Upper Critical Solution Temperature (UCST) behaviour is 523 
observed for the IsoNA/xylitol system with the critical temperature calculated to be 524 
110°C. Such result indicates complete IsoNA-xylitol miscibility at temperatures 525 
greater than 110°C, in conformity with the miscibility boundary suggested by the 526 
concave ΔGmix/RT curves in Figure 4b. However, it is worth noting that the negative 527 
ΔGmix/RT values at all proportions on the sigmoidal energy curve at 100°C (Figure 528 
4b), although signifies thermodynamically favoured mixing, still exhibits a 10°C 529 
difference than what would be required for ideal mixing (UCST).  530 
 531 
Hot-melt Extrusion with Predetermined Temperature Profiles and Screw Configuration 532 
Profiles 533 
Phase Diagrams and relevance to Processing  534 
From melting depression data previously discussed, ideal mixing would occur below 535 
95°C between ibuprofen and xylitol, however above 110°C to ensure (or at least 536 
higher than 100°C to favour) dissolution of isonicotinamide in the molten xylitol. 537 
Moreover, processing should be carried out above 115°C to facilitate precipitation of 538 
cocrystal product from the xylitol melt (LCST at 114°C and all-proportion negative 539 
ΔGmix/RT values above 115°C). Using this theoretical framework makes it 540 
impossible to identify a processing window that would be ideal for mixing of parent 541 
reagents with xylitol whilst encouraging precipitation of the cocrystal product 542 
(Figure 6). Despite this, our previous work successfully prepared an equimolar Ibu-543 
IsoNA cocrystal (albeit with relatively low yield) at 92°C, the temperature being 544 
selected to correspond to the onset melting temperature for xylitol, in a HAAKE 545 
Minilab conical twin-screw extruder1.  546 
In order to understand how useful the F-H theory is with respect to manufacture 547 
of cocrystal material and in identifying relevant processing windows, temperatures 548 
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previously shown to be critical in both the energy curves and T-Φ phase diagrams 549 
(80, 95, 100, 110 and 115°C, respectively) were used for Zone 1 during extrusion. 550 
This zone was used as a melt zone for the ternary system, consisting of an equimolar 551 
Ibu-IsoNA premix blended with xylitol at a 1:1 mass ratio. The feed zone (Zone 0) 552 
upstream to Zone 1 was kept constant at 60°C to allow adequate solid conveying. 553 
Zones 2 and 3 downstream to the melt Zone 1 were set at gradually cooled 554 
temperatures to ensure solidification of the extrudates. The respective temperature 555 
profiles (TPs) were named as TP1-TP5 (Table 1), respectively. 556 
Extrusion trials 1-5 were conducted with a full set of conveying screw elements 557 
(SCP1). As shown in Figure 7, when SCP1 was used, temperature profiles TP1, TP2 558 
and TP3 resulted in low but gradually increasing cocrystal yields (9.0±0.2%, 559 
9.7±1.2% and, 12.6±2.0% respectively). TP4 gave the highest yield of 31.4±1.9% 560 
with TP5 showing a small but significant decrease in yield to 22.1±1.2%. 561 
Interestingly, according to previous phase diagram predictions, although 110°C 562 
(TP4 melting zone temperature) is favouring IsoNA dissolution in the xylitol melt, 563 
this temperature is unfavourable for miscibility between xylitol and ibuprofen. If 564 
based on the original hypothesis that dissolution of both parent coformers is 565 
required for cocrystallisation, TP4 should result in just as low cocrystal yield as TP1 566 
and TP2. However, it was clearly evident that IsoNA/xylitol miscibility (as with TP4) 567 
played a more dominant role in driving cocrystallisation to higher yield, whereas 568 
the influence of xylitol/ibuprofen miscibility (as with TPs1-3) was much less 569 
pronounced. This is probably because when dissolved in the xylitol melt, the 570 
conformational freedom open to IsoNA molecules is significantly enhanced at 571 
various interfaces, so there is greater probability for molecular collision53. With 572 
regard to ibuprofen, on the other hand, melting of the drug occurred at all 573 
investigated processing temperatures, and thus, there was already a high ibuprofen 574 
molecular mobility5. It also appeared that there was no significant impact on 575 
cocrystal yield whether molten ibuprofen was miscible (TP1) or immiscible (TP2 & 576 
TP3) with xylitol. In fact, FTIR analysis within our preliminary investigations 577 
showed no evidence of molecular interaction between ibuprofen and xylitol 578 
molecules in a mixture prepared by melting followed with quench cooling. This 579 
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would have created almost a competing environment between the molten ibuprofen 580 
and the molten xylitol to interact with the dissolved IsoNA molecules. Therefore, it 581 
would be crucial that the interactions responsible for IsoNA-xylitol miscibility are 582 
not substantially stronger than that responsible for the ibuprofen-IsoNA 583 
cocrystallisation.  584 
It is also worth noting that when using 100°C as the melting zone temperature 585 
(TP3), although the energy curve predicted negative ΔGmix at all compositions 586 
(suggesting favoured IsoNA/xylitol mixing), the cocrystal conversion yielded from 587 
TP3 (12.6±2.0%) was only 1/3 of that from TP4 (31.4±1.9%). Since the temperature 588 
setting (110°C) used in TP4 was the UCST in the binary system denoting boundary 589 
of complete IsoNA/xylitol miscibility, significant cocrystal yield increasing from TP4 590 
is suggesting that the critical temperature prediction using the T-φ phase diagram 591 
may offer more guidance in selecting processing temperature rather than a simple 592 
reliance on temperatures when ∆Gmix is negative.   593 
The phase diagrams also suggested cocrystal/xylitol phase separation at 594 
temperatures higher than 114°C (the LCST). Since Zone 2 and Zone 3 were set at 595 
gradually decreasing temperatures to allow sufficient solidification for xylitol, it is 596 
presumed that the Ibu-IsoNA cocrystal would precipitate out from the xylitol melt in 597 
the melting Zone 1, where phase separation is thermodynamically favoured. 598 
Moreover, the precipitation of the cocrystal from xylitol might drive further 599 
dissolution of IsoNA into the molten carrier. Therefore, it was anticipated that TP5, 600 
having 115°C set as the melting zone temperature, should result in further increased 601 
cocrystal yield than TP4. However, with full conveying screw geometry (SCP1), the 602 
resulted yield from TP5 was only 2/3 (22.1±1.2%) of that from TP4. Although such 603 
result seems to suggest inaccuracy of the cocrystal/xylitol phase diagram 604 
predictions, one should remember that, in extrusion, it is common to have a higher 605 
melt temperature than the set values. Such temperature variations are typically the 606 
result of local temperature fluctuations derived from the frictional heat generated 607 
during shearing. In the current work, the LCST denoting cocrystal/xylitol phase 608 
separation (114°C) was too close to the onset of cocrystal melting (120.21±0.26°C). 609 
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With increasing cocrystal yield and hence increased amount of solid content, the 610 
frictional heat accumulation increases, and so does the regional temperature. Once 611 
the local temperature rise approaches close to the cocrystal melting temperature, 612 
the newly formed cocrystal would start to melt. If the cocrystal melting overweighs 613 
their increased formation, a reduced overall yield (relative to TP4) would be 614 
measured. Therefore, while using the T-φ phase diagram to predict the HME 615 
processing window for cocrystal suspensions, the influence of the mechanical 616 
shearing upon phase transition, such as melting, of the cocrystal components should 617 
not be ignored.  618 
 619 
Screw Configuration and Cocrystal Yield 620 
When extruding the binary mixture of a coformer pair, increased mixing intensity 621 
has been reported to contribute to improved cocrystal yield5. It is of interest to see 622 
how varying the level of mixing could impact upon cocrystal yield, particularly in 623 
this complex ternary system consisting of a coformer pair and a matrix carrier 624 
(xylitol). More importantly, it is interesting to understand how this information can 625 
be used to design a screw configuration that drives improved cocrystallisation.  626 
Consequently, the ternary blend consisting of premixed equimolar Ibu-IsoNA and 627 
xylitol at 50:50 weight ratio was subjected to two additional screw configurations 628 
SCP2 and SCP3, respectively. Initially, both the SCP2 and SCP3 contain forward 629 
conveying elements for the feed Zone 0 to ensure material transport (Figure 8a). To 630 
facilitate mixing and the subsequent formation of cocrystals, kneading blocks were 631 
introduced to Zone 1.  The kneading block designs are the most commonly used 632 
mixing element among numerous element designs for co-rotating twin-screw 633 
extruders. This is due to their mixing efficiency and self-wiping nature. A block of 634 
kneading discs, are usually described as stagger angle between two adjacent discs, 635 
number of discs in one block and overall length of the block. The kneading blocks 636 
used in this study include 60/4/10 elements (60° stagger angle with 4 discs forming 637 
a 10mm long block), and 90/4/10 elements for SCP2 and SCP3, respectively. 638 
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Generally speaking, for kneading blocks that are arranged in a forward conveying 639 
direction, a smaller stagger angle provides more positive melt flow (pumping 640 
capability). A kneading element with a perpendicular disc design (a 90° stagger 641 
angle) is called a neutral kneading block that has neither forward nor reverse 642 
conveying attributes. The conveying of materials through a neutral block is entirely 643 
dependent upon forward conveying elements upstream the block to compensate for 644 
the lack of conveying action in the neutral kneading region54,55. Therefore, an 645 
increased number of neutral kneading blocks usually results in increased extrusion 646 
residence time owing to reduced forward conveying capacity. Figure 8b shows the 647 
detailed kneading block arrangement employed in SCP2. A 90/4/10 block was 648 
sandwiched between two 60/4/10 blocks. A gradually increasing then ‘phase out’ 649 
sequence is usually deemed necessary to provide a transition between complete 650 
forward flow and complete stagnation so that local pressure within the neutral 651 
kneading region does not increase dramatically. The same sequence was used both 652 
in Zone 1 and between Zone 2 and Zone 3 in (Table 2, SCP2). It is worth noting that 653 
two separate kneading regions were used to prevent excessive stagnation of the 654 
melt flow. The measured cocrystal yields are shown in Table 3, (SCP 2, formulations 655 
6-10). In general, the percent cocrystal yield was dependent upon Zone 1 656 
temperature setting, with 13.8±0.3%, 13.9±0.1%, 20.6±0.4% and 44.2±0.3% 657 
measured for TP1-4, respectively, and 30.5±0.8% for TP5. The incorporation of 658 
kneading sections was evidently in favour of increased cocrystal yield. Moreover, 659 
the overall correlation between the cocrystal yield and the TP settings was still in 660 
agreement with what had been previously achieved using full convey screw 661 
configuration (SCP1). TP5, although anticipated to offer further increased cocrystal 662 
yield according to the T-φ phase diagram predictions, resulted in a reduced yield 663 
than TP4. This, again, emphasises the importance of mechanical input during HME, 664 
its impact upon local temperature fluctuation and phase transition (i.e. melting) of 665 
the produced cocrystal.  666 
In addition, the stagger angle between adjacent kneading discs controls the inter-667 
disk leakage, which dictates whether the kneading unit is more prone to dispersive 668 
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or distributive mixing (Figure 9). Kneading elements that show a smaller stagger 669 
angle or broader kneading disc thickness typically contribute to increased 670 
dispersive mixing, whereas those with larger stagger angle or narrower disc 671 
thickness result in increased distributive mixing7,55–58. As suggested by the phase 672 
diagram and also identified in previous extrusion trials Zone 1 is the region of the 673 
extruder where there are melting of ibuprofen and xylitol, dissolution of IsoNA into 674 
molten xylitol, and precipitation of cocrystal from the xylitol melt. Given the 675 
complexity involved in this zone, an attempt was made to separate the nature of 676 
mixing in Zone 1. As Table 2 shows, two 0/2/10 sections were introduced to Zone 1 677 
in SCP3 in order to provide additional dispersive mixing. These two half sections 678 
were configured as shown in Figure 8c. The incorporation of such elements to the 679 
first kneading region was to enhance dissolution of IsoNA in xylitol, a process that 680 
was shown to be essential for cocrystallisation. It was considered that the dispersive 681 
mixing sections might improve IsoNA-xylitol molecular dispersion as well as 682 
facilitate Ibu-IsoNA molecular collision, hence improving cocrystallisation 683 
efficiency59–62. Whilst in the second kneading region, the SCP3 employed an 684 
additional 90/4/10 block in order to offer prolonged distributive mixing, thus 685 
improving distribution of the cocrystal particulates suspended within the xylitol 686 
matrix without further reducing the particle size and rendering them amorphous. 687 
Further enhanced cocrystal yield was obtained with SCP3 at all extrusion TP 688 
settings. In particular, TPs 1-4 resulted in 19.9±3.1%, 18.1±0.9%, 35.0±2.9% and, 689 
58.8±1.8% cocrystal yielding, respectively, whilst TP5 resulted in a 39.8±1.7% yield. 690 
All results show good agreement with our SCP design hypothesis and previous 691 
discussion.   692 
Page 26 of 50
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  27
CONCLUSION 693 
In this study, we report for the first time the use of phase diagrams derived from F-694 
H theory in (1) determining miscibility behaviour; (2) selection of matrix carrier 695 
and; (3) providing guidance on HME processing temperature for cocrystal ternary 696 
systems. The use of small-scale thermal analysis and the adaptation of the Flory-697 
Huggins theory provide useful information such as binary solubility and correlation 698 
between such solubility and temperature. This information was used in an attempt 699 
to predict the conditions under which cocrystal yield could be significantly 700 
improved. The construction of phase diagrams was useful in determining the HME 701 
processing temperature at which cocrystal yield may be thermodynamically 702 
favoured whereas screw profile experiments have shown that screw geometry 703 
modification can also be employed to alter cocrystal yield. By optimum selection of 704 
processing temperature and careful choice of extruder screw design, we have 705 
obtained cocrystal yield of approximately 60% in the presence of a matrix carrier. It 706 
is important to note that such a conversion ratio was achieved on a bench-top lab-707 
scale extrusion compounder. Through the use of larger processing equipment, 708 
greater flexibility would be available in terms of both temperature setting and screw 709 
profile across the barrel. This may allow for improved control and hence further 710 
increased yield of cocrystal during scale-up. 711 
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Table 1 Temperature profile settings TP1~TP5 designed to provide different 
thermodynamic environment for various degrees of mixing among raw 
ingredients. 
 
Zone 0  
°C 
Zone 1  
°C 
Zone 2  
°C 
Zone 3  
°C 
TP1 60 80 80 80 
TP2 60 95 85 80 
TP3 60 100 90 80 
TP4 60 110 95 80 
TP5 60 115 100 80 
Extrusion 
direction 
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Table 2 Specification of the screw configuration profile on one assembly shaft 
arranged from underneath the feed throat to the discharge end. 
No.* 
SCP1 
No. 
SCP2 
No. 
SCP3 
Element type Element type Element type 
19 Forward conveying 6 Forward conveying 6 Forward conveying 
1 End unit 1 60° kneading 0.75 60° kneading 
  1 90° kneading 0.5 0° kneading 
  1 60° kneading 0.5 60° kneading 
 Screw tip 4 Forward conveying 0.5 0° kneading  
  1 60° kneading 0.75 90° kneading 
  1 90° kneading 1 60° kneading 
  1 60° kneading 3 Forward conveying 
  3 Forward conveying 1 60° kneading 
  1 End unit 2 90° kneading 
   Screw tip 1 60° kneading 
    2 Forward conveying 
    1 End unit 
     Screw tip 
* Number of element unit (Length/Diameter).  
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Table 3 Nomenclature and process conditions for the hot-melt extruded 1:1 Ibu-IsoNA cocrystal suspensions. Note that Ibu and IsoNA were 
premixed at a 1:1 molar ratio, whereas the weight fraction of xylitol in the ternary mixture was 50wt% for all extruded formulations. 
Formulation 
Temperature 
profile 
Screw 
configuration 
profile 
Zone 0 Zone 1 Zone 2 Zone 3 Cocrystal 
Yield 
(%) 
Actual recordings (°C) 
1 TP1 
SCP1 
60.3±0.28 80.2±0.14 80.0±0.07 80.0±0.00  9.0 ± 0.2 
2 TP2 60.4±0.64 95.2±0.35 87.8±1.20 80.2±0.07 9.7 ± 1.2 
3 TP3 63.0±1.20 100.2±0.28 91.6±0.49 82.6±0.57 12.6 ± 2.0 
4 TP4 66.6±2.33 110.2±0.21 101.4±0.28 87.9±0.57 31.4 ± 1.9 
5 TP5 66.4±2.05 115.4±0.14 104.1±0.28 89.2±0.71 22.1 ± 1.2 
6 TP1  60.1±0.14 80.2±0.07 80.65±0.21 80.0±0.07 13.8 ± 0.3 
7 TP2  60.2±0.21 95.1±0.14 88.2±0.21 80.3±0.14 13.9 ± 0.1 
8 TP3 SCP2 61.6±0.49 100.2±0.14 93.2±0.28 88.3±0.28 20.6 ± 0.4 
9 TP4  63.0±0.57 110.2±0.07 105.3±0.57 90.2±3.04 44.2 ± 0.3 
10 TP5  65.9±0.14 115.4±0.28 107.0±0.14 91.5±0.85 30.5 ± 0.8 
11 TP1  60.0±0.07 80.4±0.42 81.1±0.28 80.0±0.07 19.9 ± 3.1 
12 TP2  60.0±0.00 95.0±0.00 87.8±0.99 81.1±1.56 18.1 ± 0.9 
13 TP3 SCP3 60.3±0.28 100.2±0.28 95.0±0.35 86.0±2.69 35.0 ± 2.9 
14 TP4  62.8±0.35 110.0±0.07 102.6±2.62 89.0±4.17 58.8 ± 1.8 
15 TP5  65.5±0.42 115.1±0.14 107.0±0.21 90.8±2.55 39.8 ± 1.7 
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 Fdi Fpi Ehi Vi V δd δp
J0.5·cm1.5/mol J0.5·cm1.5/mol J/mol cm3/mol cm3/mol MPa0.5 MPa0.5 M
1 1270 110 0 -
CHaromatic 4 - - - 13.42
Caromatic 2 - - - 7.42
–CH3 3 420 0 0 21.55
–CH2– 1 270 0 0 15.55
>CH– 2 80 0 0 9.56
Ring 1 190 0 0 -
–COOH 1 530 420 7000 26.1
–NH2 1 280 0 8400 17
–CO– 1 290 770 2000 17.3
Ring 1 190 0 0 -
=N- 1 20 800 5000 12.6
=CH– 4 200 0 0 13.18
=C< 1 70 0 0 8.18
–OH 5 210 500 20000 12.45
–CH2– 2 270 0 0 15.55
>CH– 3 80 0 0 9.56
2 1270 110 0 -
CHaromatic 8 - - - 13.42
Caromatic 4 - - - 7.42
–CH3 6 420 0 0 21.55
–CH2– 2 270 0 0 15.55
>CH– 4 80 0 0 9.56
–COOH 2 530 420 7000 26.1
–NH2 2 280 0 8400 17
–CO– 2 290 770 2000 17.3
Ring 4 190 0 0 -
=N- 2 20 800 5000 12.6
=CH– 8 200 0 0 13.18
=C< 2 70 0 0 8.18
Isonicotinamide equimolar cocrystal
603.48 17.66 2.79
122.03 15.00 9.16
2.24
Isonicotinamide
107.80 15.31 10.30
Compound Group Quantity
Ibuprofen
193.94 18.97
de 
er 
Carboxylic acid-pyridine 
synthon 
xylic acid-pyridine 
on 
Compound structure and the calculated solubility parameters with component group contributions (group contributions obtained 
Polymer Handbook
15
.  
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Table 5 The molecular weights, true densities and melting temperatures of each individual compound used in the Flory-Huggins calculations. 
The melting temperature shown here represents the mean±SD of three replicates. Note that the melting temperature of Isonicotinamide 
was determined at a heating rate of 200°C/min to minimise influenced by sublimation. 
Compound 
Mw 
g/mol 
ρ* 
g/cm
3 
Tm (onset) 
°C 
Tm (peak) 
°C 
Tm(end) 
°C 
ΔH 
J/g 
Ibuprofen 206.30 1.08 75.37±0.22 76.42±0.06 78.86±0.08 123.87±4.08 
Isonicotinamide 122.12 1.34 155.37±0.45 162.58±0.97 169.79±1.62 199.21±9.80 
Reference cocrystal 656.48 1.18 120.21±0.26 120.73±0.04 120.96±0.06 128.42±1.91 
Xylitol 152.15 1.52 93.95±0.31 95.00±0.13 95.32±0.14 229.36±10.64 
 *The RSD for true density in the above measurements were all less than 0.07.  
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Figure legends 
Figure 1 Schematic illustration of cocrystallisation mechanism, inside the extruder barrel, 
from a non-complementary carrier excipient.  
Figure 2 DSC thermograms of (a) xylitol/Ibu mixtures obtained using a heating rate of 
1°C/min; (b) IsoNA/xylitol mixtures obtained using a heating rate of 200°C/min; and (c) 
reference cocrystal/xylitol mixtures obtained using a heating rate of 1°C/min with various 
compositions. 
Figure 3 The linear fit of the F-H interaction parameter χ and 1/T in Xylitol systems: (A) 
Ibu-Xylitol; (B) Isonicotinamide-Xylitol; and (C) equimolar cocrystal-Xylitol blends, 
respectively.  
Figure 4 A plot of ΔGmix/RT versus composition for (a) Ibu/xylitol, (b) IsoNA/xylitol and (c) 
reference cocrystal/xylitol mixtures, respectively, at various temperatures:  80°C;   92°C; 
 95°C;  100°C;  110°C;  115°C and,  120°C. 
Figure 5 Liquid-solid phase transition diagrams for (a) xylitol/ibuprofen, (b) IsoNA/xylitol 
and (c) ref-cocrystal/xylitol mixtures, respectively. The solid diamonds represent the 
average χ determined from (n=3) replicate melting depression experiments, the dashed is 
the predicted solid-liquid line; the crosses give the F-H spinodal decomposition curve; and 
the solid triangle represents the critical solution temperature. 
Figure 6 Overlain T-Φ spinodal lines for (from top down): cocrystal/xylitol, IsoNA/xylitol 
and, ibuprofen/xylitol systems, respectively. The arrows indicate regions in which 
respective phase behaviour (miscibility or separation) would occur based on the critical 
temperature predictions. It is clear that for the studied ternary system, an ideal HME 
processing window that meets all hypothesised criteria does not exist. 
Figure 7 Calculated cocrystal yield from the melt-extruded suspensions. The pattern of the 
column represents the screw configuration profile: (blue) full-conveying profile SCP1, 
(green) intermediate intensity mixing profile SCP2, and (red) high intensity mixing profile 
SCP3, respectively. The label at the outer end of each column is the calculated average yield 
in percentage from 5 replicates. Note the columns are grouped according to the melting 
zone temperature setting. 
Figure 8 Arrangement of: (a) forward conveying regions; (b) kneading regions used in SCP 
2; (c) kneading region with two half-a-block-long 0° dispersive mixing sections in SCP 3 and; 
(d) consecutive neutral kneading sections in SCP 3. 
Figure 9 Illustrative sketches showing the distribution and dispersion of materials in the 
staggering kneading region of an intermeshing modular twin-screw extruder: (a) 
distributive mixing caused by forcing material to flow around the kneading discs of a 
90/4/10 block; (b) dispersive mixing flow of a 60/4/10 block caused by forcing material to 
flow through the narrow gap between the top of the shearing disc tip and the interior wall 
of extruder barrel. 
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Table captions 
Table 1 Temperature profile settings TP1~TP5 designed to provide different 
thermodynamic environment for various degrees of mixing among raw ingredients.  
Table 2 Specification of the screw configuration profile on one assembly shaft arranged 
from underneath the feed throat to the discharge end.  
Table 3 Nomenclature and process conditions for the hot-melt extruded 1:1 Ibu-IsoNA 
cocrystal suspensions. Note that Ibu and IsoNA were premixed at a 1:1 molar ratio, whereas 
the weight fraction of xylitol in the ternary mixture was 50wt% for all extruded 
formulations.  
Table 4 Compound structure and the calculated solubility parameters with component 
group contributions (group contributions obtained from Polymer Handbook
15
.  
Table 5 The molecular weights, true densities and melting temperatures of each individual 
compound used in the Flory-Huggins calculations. The melting temperature shown here 
represents the mean±SD of three replicates. Note that the melting temperature of 
Isonicotinamide was determined at a heating rate of 200°C/min to minimise influenced by 
sublimation.  
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Figure 1 Schematic illustration of cocrystallisation mechanism, inside the extruder barrel, from a non-
complementary carrier excipient.  
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Figure 2 DSC thermograms of (a) xylitol/Ibu mixtures obtained using a heating rate of 1°C/min; (b) 
IsoNA/xylitol mixtures obtained using a heating rate of 200°C/min; and (c) reference cocrystal/xylitol 
mixtures obtained using a heating rate of 1°C/min with various compositions.  
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Figure 3 The linear fit of the F-H interaction parameter χ and 1/T in Xylitol systems: (A) Ibu-Xylitol; (B) 
Isonicotinamide-Xylitol; and (C) equimolar cocrystal-Xylitol blends, respectively.  
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Figure 4 A plot of ∆Gmix/RT versus composition for (a) Ibu/xylitol, (b) IsoNA/xylitol and (c) reference 
cocrystal/xylitol mixtures, respectively, at various temperatures: 80°C; 92°C; 95°C; 100°C; 110°C; 115°C 
and, 120°C, respectively.  
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Figure 5 Liquid-solid phase transition diagrams for (a) xylitol/ibuprofen, (b) IsoNA/xylitol and (c) ref-
cocrystal/xylitol mixtures, respectively. The solid diamonds represent the average χ determined from (n=3) 
replicate melting depression experiments, the dashed is the predicted solid-liquid line; the crosses give the 
F-H spinodal decomposition curve; and the solid triangle represents the critical solution temperature.  
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Figure 6 Overlain T-Φ spinodal lines for (from top down): cocrystal/xylitol, IsoNA/xylitol and, 
ibuprofen/xylitol systems, respectively. The arrows indicate regions in which respective phase behaviour 
(miscibility or separation) would occur based on the critical temperature predictions. It is clear that for the 
studied ternary system, an ideal HME processing window that meets all hypothesised criteria does not exist. 
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Figure 7 Calculated cocrystal yield from the melt-extruded suspensions. The pattern of the column 
represents the screw configuration profile: (blue) full-conveying profile SCP1, (green) intermediate intensity 
mixing profile SCP2, and (red) high intensity mixing profile SCP3, respectively. The label at the outer end of 
each column is the calculated average yield in percentage from 5 replicates. Note the columns are grouped 
according to the melting zone temperature setting.  
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Figure 8 Arrangement of: (a) forward conveying regions; (b) kneading regions used in SCP 2; (c) kneading 
region with two half-a-block-long 0° dispersive mixing sections in SCP 3 and; (d) consecutive neutral 
kneading sections in SCP 3.  
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Figure 9 Illustrative sketches showing the distribution and dispersion of materials in the staggering kneading 
region of an intermeshing modular twin-screw extruder: (a) distributive mixing caused by forcing material to 
flow around the kneading discs of a 90/4/10 block; (b) dispersive mixing flow of a 60/4/10 block caused by 
forcing material to flow through the narrow gap between the top of the shearing disc tip and the interior wall 
of extruder barrel.  
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